Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + toripalimab + dacarbazine for advanced melanoma
ChiCTR2400083074Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, toripalimab and dacarbazine in melanoma, sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Started Apr 2024; status: recruiting.
02
Drugs
bevacizumabtoripalimabdacarbazine
03
Conditions
melanoma
Beyond the preview
Go deeper on ChiCTR2400083074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083074.